Key facts
- This page summarizes Christopher Mills's Form 3 filing for Renalytix plc (RNLXY).
- 0 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 03 Jul 2023, 16:23.
Key filing fact
Ownership activity is grounded in SEC Form 3 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
No transaction description listed
No transaction description listed
No transaction description listed
Additional SEC filing notes
Footnote F1
The Ordinary Shares may be represented by American Depositary Shares, each representing two Ordinary Shares.
Footnote F2
The securities are directly held by North Atlantic Smaller Companies Investment Trust plc ("North Atlantic"). The Reporting Person is the Partner and Chief Investment Officer of Harwood Capital LLP ("Harwood"). Harwood is the Investment Manager to North Atlantic. The Reporting Person disclaims beneficial ownership of the securities held by North Atlantic except to the extent of his pecuniary interest therein.
Footnote F3
The securities are directly held by Oryx International Growth Fund Limited ("Oryx"). The Reporting Person is the Partner and Chief Investment Officer of Harwood. Harwood is the investment adviser to Oryx. The Reporting Person disclaims beneficial ownership of the securities held by Oryx except to the extent of his pecuniary interest therein.
Footnote F4
The securities are directly held by Harwood. The Reporting Person is the Partner and Chief Investment Officer of Harwood. The Reporting Person disclaims beneficial ownership of the securities held by Harwood except to the extent of his pecuniary interest therein.
SEC remarks
Exhibit List - Exhibit 24 - Power of Attorney